Straits Times Index
3,313.48 +8.49 (+0.26%) Nikkei
38,787.38 -132.88 (-0.34%) Hang Seng
19,553.61 +177.08 (+0.91%) FTSE 100
8,420.26 -18.39 (-0.22%) Bitcoin USD
66,880.95 +1,254.24 (+1.91%) CMC Crypto 200
1,369.64 -4.20 (-0.31%)
Novo Nordisk A/S (NOVO-B.CO)
| Previous close | 912.90 |
| Open | 911.00 |
| Bid | 901.90 x 0 |
| Ask | 903.30 x 0 |
| Day's range | 901.10 - 919.00 |
| 52-week range | 504.40 - 932.00 |
| Volume | |
| Avg. volume | 2,701,315 |
| Market cap | 4.024T |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 45.46 |
| EPS (TTM) | 19.87 |
| Earnings date | 07 Aug 2024 |
| Forward dividend & yield | 12.80 (1.42%) |
| Ex-dividend date | 22 Mar 2024 |
| 1y target est | 920.44 |
ZacksPharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates
Bayer (BAYRY) releases Q1 results. J&J (JNJ) set to acquire private biotech, Proteologix, which will add atopic dermatitis candidates.
GlobeNewswireNovo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 17 May 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiate
Zacks4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
